Biognosys has announced the commercial availability of the NULISA proteomics assays for biomarker discovery in plasma and other biofluids. Under a strategic partnership with Alamar Biosciences, the developer of the NULISA platform, Biognosys has become the preferred provider of NULISA multiplex assay services for biopharma research. The NULISAseq CNS Disease and Inflammation panels are now available as a contract research service from Biognosys' advanced proteomics facility in Europe.

The NULISAseq CNS Disease 120 and Inflammation 250 panels are being offered at Biognosys' Swiss facility, providing expert curation for multiplexed analysis of elusive cytokines, chemokines, and key disease-specific neurodegeneration markers such as pTau217. It is claimed to be able to provide information from a biofluids sample as small as 10ul. Biognosys also aims to combine Alamar’s NULISA targeted panels with its mass spectrometry-based TrueDiscovery platform, powered by the P2 Plasma Enrichment System, to offer a holistic plasma proteomics collection. 

Analyst QuickTake: The collaboration between Biognosys and Alamar Biosciences was first established in April 2024 to research biofluid-based proteomics. They planned to integrate Biognosys' DIA-MS (data independent acquisition mass spectrometry) expertise and Alamar's immunoassays, such as NULISA assays for low-abundance proteins such as cytokines, chemokines, and important disease protein biomarkers from plasma.